secwatch.observer — SEC 8-K summary
======================================

Issuer:     PROTHENA CORP PUBLIC LTD CO (PRTA)
CIK:        0001559053
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001559053-24-000023
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prothena Q2 net income $66.9M; BMS licenses PRX019 for $80M; year-end cash guidance raised to $468M
--------------------------------------------------------------------------------

- Q2 net income $66.9M (diluted EPS $1.22) vs net loss $54.6M in Q2 2023; revenue $132M vs $4M.
- BMS obtained exclusive global license for PRX019 for $80M upfront; potential milestones up to $617.5M.
- Year-end cash guidance raised to ~$468M from $405M; net cash used guidance reduced to $148-160M.
- Topline results expected: prasinezumab Phase 2b (2H 2024), birtamimab Phase 3 (4Q24-2Q25), coramitug Phase 2 (1H25).
- Cash and restricted cash $565M as of June 30, 2024; no debt; ~53.8M shares outstanding.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1559053/000155905324000023/0001559053-24-000023-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1559053/000155905324000023/prta-20240808.htm
  HTML page:      https://secwatch.observer/filing/0001559053-24-000023

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer